TY - JOUR
T1 - Markers of Cardiovascular Risk Associated with Pregnancy
AU - Quesada, Odayme
AU - Scantlebury, Dawn C.
AU - Briller, Joan E.
AU - Michos, Erin D.
AU - Aggarwal, Niti R.
N1 - Funding Information:
Dr. Quesada is supported by the NIH K23-HL151867. Dr. Michos is supported by the Amato Fund in Women’s Cardiovascular Health at Johns Hopkins University. Dr. Michos reports Advisory Boards with Amarin, AstraZenca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, and Pfizer. Dr. Briller is an unpaid consultant for the Illinois Maternal Mortality Committee and is on the Steering committee for the REBIRTH trial of bromocriptine in Peripartum Cardiomyopathy (NCT05180773).
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/2
Y1 - 2023/2
N2 - Purpose of Review: The purpose of the review is to summarize the unique cardiovascular disease (CVD) risk factors encountered during pregnancy and to provide the reader with a framework for acquiring a comprehensive obstetric history during the cardiovascular (CV) assessment of women. Recent Findings: Individuals with a history of pregnancies complicated by hypertensive disorders of pregnancy (HDP), gestational diabetes (GDM), preterm delivery, low birth weight, and fetal growth restriction during pregnancy are at a higher risk of developing short- and long-term CV complications compared to those without adverse pregnancy outcomes (APOs). Women with a history of APOs can be at increased risk of CVD even after achieving normoglycemia and normal blood pressure control postpartum. Risk assessment and stratification in women must account for these APOs as recommended by the 2019 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the primary prevention of CVD. Early recognition, monitoring, and treatment of APOs are key to limiting CVD complications late in maternal life. Summary: Recognition of APOs as female-specific cardiovascular risk factors is critical for risk stratification for women and birthing persons. Further research is needed to understand the complex interplay between genetics, environmental, behavioral, and maternal vascular health, and the association between APOs and CVD risk.
AB - Purpose of Review: The purpose of the review is to summarize the unique cardiovascular disease (CVD) risk factors encountered during pregnancy and to provide the reader with a framework for acquiring a comprehensive obstetric history during the cardiovascular (CV) assessment of women. Recent Findings: Individuals with a history of pregnancies complicated by hypertensive disorders of pregnancy (HDP), gestational diabetes (GDM), preterm delivery, low birth weight, and fetal growth restriction during pregnancy are at a higher risk of developing short- and long-term CV complications compared to those without adverse pregnancy outcomes (APOs). Women with a history of APOs can be at increased risk of CVD even after achieving normoglycemia and normal blood pressure control postpartum. Risk assessment and stratification in women must account for these APOs as recommended by the 2019 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the primary prevention of CVD. Early recognition, monitoring, and treatment of APOs are key to limiting CVD complications late in maternal life. Summary: Recognition of APOs as female-specific cardiovascular risk factors is critical for risk stratification for women and birthing persons. Further research is needed to understand the complex interplay between genetics, environmental, behavioral, and maternal vascular health, and the association between APOs and CVD risk.
KW - CardioObstetrics
KW - Gestational diabetes
KW - Hypertensive disorders of pregnancy
KW - Preclampsia
KW - Pregnancy
KW - Women cardiac risk
UR - http://www.scopus.com/inward/record.url?scp=85147561669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147561669&partnerID=8YFLogxK
U2 - 10.1007/s11886-022-01830-1
DO - 10.1007/s11886-022-01830-1
M3 - Review article
C2 - 36745273
AN - SCOPUS:85147561669
SN - 1523-3782
VL - 25
SP - 77
EP - 87
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 2
ER -